Unlike in Europe, Canada, and much of the rest of the world, oral testosterone undecanoate is not available in the United States. Unmodified testosterone was also formerly available for intramuscular injection but was discontinued. Intramuscular testosterone undecanoate was not introduced in Europe and the United States until much later (in the early to mid 2000s and 2014, respectively). In the 1970s, testosterone undecanoate was introduced for oral use in Europe, although intramuscular testosterone undecanoate had already been in use in China for several years. In the mid-1950s, the longer-acting testosterone esters testosterone enanthate and testosterone cypionate were introduced. This is due to steric hindrance of C17β-position metabolism during the first-pass through the liver.
See "What is the most important information I shouldknow about Vogelxo? Using Vogelxo with certain other medicines you take canaffect each other. Tell your healthcare provider about all the medicines youtake, including prescription and overthe-counter medicines, vitamins, andherbal supplements. What is the most important information I should knowabout Vogelxo? A mean (SD) of0.16 (0.46) to 0.65(1.03) μg of residual testosterone (i.e., 99% reductioncompared to when hands were not washed) was recovered after washing hands withliquid soap and warm water. Under these study conditions, unprotected female partnershad a mean testosterone AUC0-24 and Cmax that were 2.8 and 4 times greater thantheir mean baseline values, respectively.
Another C17β ether prodrug of testosterone, silandrone, also exists but was never marketed, and is notable in that it is orally active. A C17β ether prodrug of testosterone, cloxotestosterone acetate, has also been marketed, although it is little known and is used very rarely or no longer. Major testosterone esters include testosterone cypionate, testosterone enanthate, testosterone propionate, and testosterone undecanoate. These include oral, buccal, sublingual, intranasal, transdermal (gels, creams, patches), rectal suppositories), by intramuscular or subcutaneous injection (in oil or aqueous), and as a subcutaneous implant.
Of 192 hypogonadal men who were appropriately titratedwith testosterone gel and who had sufficient data for analysis, 74% achieved anaverage serum testosterone level within the normal range (300 to 1,000 ng/dL)on treatment Day 90. During the first 60 days, patientswere evenly randomized to testosterone gel 50 mg, testosterone gel 100 mg,placebo gel, or testosterone transdermal system. The study wasdouble-blind for the doses of testosterone gel and placebo, but open label forthe nonscrotal testosterone transdermal system. Testosterone gel was evaluated in a randomizedmulticenter, multi-dose, active and placebo controlled 90-day study in 406adult males with morning testosterone levels ≤ 300 ng/dL. The effect of showering (with mild soap) at 1, 2 and 6hours post application of testosterone gel 100 mg was evaluated in a clinicaltrial in 12 men.
Serum concentrations oftestosterone were monitored in the female subjects for 24 hours after thetransfer procedure. About 6% of a dose is excretedin the feces, mostly in the unconjugated form. There is considerable variationin the half-life of testosterone concentration as reported in the literature,ranging from 10 to 100 minutes.
Adversereactions reported by ≥ 1% of the testosterone gel patients and greaterthan placebo are listed in Table 3. Twohundred-five (205) patients received testosterone gel 50 mg or 100 mg daily and99 patients received placebo. In a controlled clinical study, 304 patients were treatedwith testosterone gel 50 mg or 100 mg or placebo gel for up to 90 days. Our Vogelxo (testosterone) Gel Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication. Topical androgens like testosterone have been used and studied in the treatment of cellulite in women. Testosterone is under development in a low-dose intranasal formulation for the treatment of anorgasmia in women. Over the 3 to 6-month course of the studies reviewed, testosterone therapy appeared safe and generally effective, and (ruling out prostate cancer) the authors found no justification to absolutely restrict its use in men with CHF.

Gender: Female

Social links